An observational study in Primary Open Angle Glaucoma, sponsored by University of Alabama at Birmingham. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by University of Alabama at Birmingham · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.
Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 25th largest by planned enrollment of the 57 observational ones that give a count, is one of 16 that started in 2019, is one of 59 observational ones, reaches primary completion later than 32 of the 66 other live ones, and was the 230th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:
Tavo Biotherapeutics · Sites in United States
Ages 18+
Brett King · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 20–79 · Healthy volunteers
YS Life Science Co., Ltd. · Sites in United States, India
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
348 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 99 · Phase 3 58 · Phase 4 36
First in 1976; this study’s year is marked. 16 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.
Median enrollment 84 across the 279 interventional studies, 100 across the 57 observational. Of the 260 that completed or were terminated, 117 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
228 of 348 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 3 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
24 of the studies in Glaucoma, Open-Angle with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05695027Phase 3Columbia UniversityNicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study | 2027-08 |
| NCT07661329Phase 3YS Life Science Co., Ltd.A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension | 2027-11-01 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT05506423Iantrek, Inc.Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 348 studies in Glaucoma, Open-Angle with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on the other extreme. Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy that can lead to gradual loss of vision in the peripheral field and central vision. Older adults with POAG have an increased risk for motor vehicle collisions and falls. Moreover, existing studies suggest that patients with POAG exhibit more postural sway while standing as measured by a balance platform and also tend to walk more slowly than those who are normally sighted and free of ocular disease. While these disturbances likely influence mobility, there has been little research directly assessing the impact of POAG on mobility. This study will assess the impact of POAG on life space (one aspect of mobility) and will determine whether difficulties with life space are associated with difficulties experienced under conditions of dim lighting.
Aim 1: To determine whether differences exist between people with healthy eyes and patients with POAG in seeing under dim illumination (Low Luminance Questionnaire) and to determine whether such differences are associated with life space.
Aim 2: To determine whether differences exist between people with healthy eyes and patients with POAG in seeing under dim illumination (objective measures of visual function) and to determine whether such differences are associated with life space.
Patients:
Participants that are enrolled in the Early Detection of Glaucoma Progression using a Novel Individualized Approach (IRB-300000301) or in the African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the Lamina Cribrosa in Progression (IRB-161115004).
Controls:
Participants with healthy eyes will be recruited.
Inclusion Criteria (Patients):
Exclusion Criteria (Patients):
Inclusion Criteria (Controls):
Exclusion Criteria (Controls):
Patients diagnosed with primary open-angle glaucoma.
Diagnostic Test: Life Space Questionnaire · Diagnostic Test: Low Luminance Questionnaire · Diagnostic Test: Contrast sensitivity under dim illumination · Diagnostic Test: Visual field under dim illumination (MAIA) · Diagnostic Test: Macular Pigment Optical Density (MPOD) · Diagnostic Test: Dark Adaptation
Participants with healthy eyes.
Diagnostic Test: Life Space Questionnaire · Diagnostic Test: Low Luminance Questionnaire · Diagnostic Test: Contrast sensitivity under dim illumination · Diagnostic Test: Visual field under dim illumination (MAIA) · Diagnostic Test: Macular Pigment Optical Density (MPOD) · Diagnostic Test: Dark Adaptation
This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.
This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions.
Participants will be presented with visual targets of different contrast under dim illumination and asked to report when they see the target.
Sensitivity in the central visual area will be assessed under dim illumination
Participants will be asked to look at a fixation target and the density of their macular pigment will be assessed.
After adapting to a dark environment, participants will be exposed a bright flask of light. the time needed for them to recover their sensitivity will be measured.
Assessment of life space measured with the Life Space Questionnaire
The Life Space Questionnaire is a 9-item questionnaire that assesses how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame. Patients are asked to respond either Yes or No.
Time frame: Through study completion, an average of 1 year
Assessment of vision under low luminance conditions
The Low Luminance Questionnaire is a 32-item questionnaire that assesses how participants see under dim illumination and how well they can perform different tasks (e.g. reading, driving). Patients are asked to select a response among different choices on a Likert scale that ranges from 1 to 5, 1 to 6, 1 to 7, or 1 to 8 depending on the question. A response of "1" indicates that the participant experiences no difficulty while increasingly higher numbers indicate increasing amounts of difficulty.
Time frame: Through study completion, an average of 1 year
Differences in contrast sensitivity functions between controls and patients
Participants will be presented with targets of different spatial frequency at different contrasts. Their sensitivity at each spatial frequency will be recorded/
Time frame: Through study completion, an average of 1 year
Differences in dark adaptation between controls and patients
Once participants have adapted to a dark environment, they will be exposed to a bright flash of light. The time needed to recover their visual sensitivity will be measured (rod-intercept time).
Time frame: Through study completion, an average of 1 year
Differences in visual sensitivity under dim illumination between controls and patients
Participants will be presented with targets at different locations in their visual fields under dim illumination.
Time frame: Through study completion, an average of 1 year
Differences in Macular Pigment Optical Density between controls and patients
Participants will fixate on a target while their MPOD is assessed. The MPOD is measured using the Heidelberg optical coherence tomography (OCT) MPOD module. Two different light sources are directed to the back of the eye. The light is reflected back and the OCT/MPOD computes the difference in the reflectance of the two lights which is an estimate of the density of macular pigment.
Time frame: Through study completion, an average of 1 year
Assessment of the relationship between each the measure of visual function and life space
The relationship between each of the measures of visual function (dark adaptation, contrast sensitivity functions, visual fields under dim illumination, and MPOD) and life space (Life Space Questionnaire will be assessed.
Time frame: Through study completion, an average of 1 year
Assessment of the relationship between each the measure of visual function and self-reported visual function under dim illumination
The relationship between each of the measures of visual function (dark adaptation, contrast sensitivity functions, visual fields under dim illumination, and MPOD) and self-reported visual performance under dim illumination (Low Luminance Questionnaire) will be assessed.
Time frame: Through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2019 (actual). Primary completion is estimated for May 2027, 95 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion May 2026 → May 2027 and completion May 2026 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →